GNH USA

Europe — EMA

Octreoscan (Indium In-111 Pentetreotide)

GNH USA supplies Octreoscan (Indium In-111 Pentetreotide), a somatostatin analog diagnostic imaging agent for neuroendocrine tumors.

Indium In-111 Pentetreotide

Request sourcing

1
Pack/s

What is Indium In-111 Pentetreotide?

Indium In-111 Pentetreotide, the active ingredient in Octreoscan, is a somatostatin analog presented as a diagnostic imaging agent for intravenous use. It binds to somatostatin receptors, enabling visualization of neuroendocrine tumors and related lesions in patients undergoing oncologic assessment.

GNH USA supplies Octreoscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

What is Indium In-111 Pentetreotide used for?

Octreoscan is employed in the diagnostic pathway for somatostatin receptor‑positive neuroendocrine tumors. It assists clinicians in tumor localization, staging and therapy planning. - Gastroenteropancreatic neuroendocrine tumors: helps locate primary and metastatic disease for treatment planning. - Bronchial carcinoid tumors: enables detection of primary and nodal involvement. - Medullary thyroid carcinoma: assists in identifying somatostatin‑positive lesions for surgical and therapeutic decision‑making.

What are the side effects of Indium In-111 Pentetreotide?

Adverse reactions are generally mild and related to the radiopharmaceutical nature of the product.

Common Side Effects: - Nausea: mild, transient discomfort. - Flushing: brief reddening of the face or neck. - Headache: mild to moderate intensity. - Injection site pain: brief soreness at the IV site. - Transient hypotension: temporary drop in blood pressure. - Mild fatigue: short‑lasting tiredness.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rapid onset breathing difficulty and rash. - Significant hypotension: prolonged low blood pressure requiring intervention. - Radiation‑induced marrow suppression: decreased blood cell counts. - Renal toxicity: impaired kidney function in susceptible patients. - Pulmonary embolism: rare clot formation following injection. - Severe skin reactions: extensive rash or Stevens‑Johnson‑like presentation.

What precautions apply to Indium In-111 Pentetreotide?

Octreoscan should be administered only after confirming patient suitability and reviewing relevant medical history. - Pregnancy testing: avoid use in pregnant women unless benefits outweigh risks. - Breastfeeding: discontinue breastfeeding for an appropriate period after administration. - Renal function: assess kidney function; adjust protocol for impaired clearance. - Prior allergic reactions: evaluate history of hypersensitivity to radiopharmaceuticals. - Concomitant chemotherapy: consider cumulative radiation exposure. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Indium In-111 Pentetreotide interact with?

Octreoscan may interact with other agents that influence radiation exposure or somatostatin pathways.

Major Interactions (Avoid): - High‑dose peptide receptor radionuclide therapy (PRRT): additive radiation burden. - Radiolabeled antibodies: concurrent administration may increase overall radiation dose.

Moderate Interactions (Monitor Closely): - Somatostatin analog therapy (e.g., octreotide): may compete for receptor binding. - Nephrotoxic drugs (e.g., cisplatin): heightened risk of renal toxicity. - Antihistamines: may mask early signs of an allergic reaction. - Diuretics: could alter renal clearance of the radiopharmaceutical. - Calcium channel blockers: potential impact on vascular tone affecting distribution.

Frequently asked questions

What is Octreoscan used for?+
Octreoscan is a radiopharmaceutical used to image somatostatin receptor‑positive neuroendocrine tumors. It helps clinicians locate primary and metastatic lesions, assess disease extent, and plan appropriate therapeutic strategies.
How does Indium In-111 Pentetreotide work?+
Indium In-111 Pentetreotide is a somatostatin analog that binds to somatostatin receptors 2 and 5 on neuroendocrine cells. The attached indium‑111 emits gamma radiation that is captured by a gamma camera, producing detailed images of receptor‑rich tissues.
What is the usual dose of Octreoscan?+
The prescribed activity of Octreoscan is determined by the treating physician based on patient weight, tumor burden, and imaging protocol. Dosing is individualized and should follow the prescribing information and local regulatory guidance.
Is Octreoscan safe during pregnancy or breastfeeding?+
Octreoscan is generally avoided in pregnancy because radiation exposure may affect the fetus. Breastfeeding should be discontinued for a period recommended by the prescriber after administration to prevent infant exposure to radioactivity.
How do I order Octreoscan from GNH USA?+
To order Octreoscan, submit an enquiry on the product page at gnh-usa.com with the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.
How does Octreoscan compare with other imaging agents for neuroendocrine tumors?+
Octreoscan is a gamma‑emitting radiopharmaceutical that provides whole‑body imaging of somatostatin receptors, whereas newer PET agents such as Ga‑68 DOTATATE offer higher resolution and faster imaging. Choice depends on equipment availability, regulatory approval, and specific clinical questions.
What are the storage and handling requirements for Octreoscan?+
Octreoscan must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Use aseptic technique during preparation and administer promptly after reconstitution.
How is Octreoscan administered?+
Octreoscan is given as an intravenous injection under controlled conditions. After administration, imaging is typically performed 24 hours later, allowing sufficient time for tissue uptake and clearance of background activity.
What are the most serious risks associated with Octreoscan?+
Serious risks include severe allergic reactions (anaphylaxis), significant hypotension, radiation‑induced bone‑marrow suppression, and rare renal toxicity. Patients should be monitored closely during and after injection for any adverse signs.
Who should not receive Octreoscan?+
Octreoscan is contraindicated in patients with known hypersensitivity to the product, pregnant women unless benefits outweigh risks, and individuals with severe renal impairment where clearance cannot be assured.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Indium In-111 Pentetreotide
Route
Intravenous Use
Manufacturer
Curium Netherlands B.V.
Origin
EU

Related products

Octreoscan

Octreoscan

Indium In-111 Pentetreotide

Curium Netherlands B.V.
EU
Octreoscan

Octreoscan

Indium In-111 Pentetreotide

Curium Belgium Bv
EU
Octreoscan

Octreoscan

Indium In-111 Pentetreotide

Curium Netherlands B.V.
EU
Octreoscan

Octreoscan

Indium In-111 Pentetreotide

Curium Netherlands B.V.
EU